Journal article

Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.

Ian T Meredith, Stephen Worthley, Robert Whitbourn, Darren L Walters, Dougal McClean, Mark Horrigan, Jeffrey J Popma, Donald E Cutlip, Ann DePaoli, Manuela Negoita, Peter J Fitzgerald, undefined RESOLUTE Investigators

JACC Cardiovascular Interventions | Published : 2009


OBJECTIVES: The RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California). BACKGROUND: Revascularization benefits associated with current drug-eluting stents are often diminished in the presence of complex coronary lesions and in certain patient cohorts. Resolute uses a new proprietary polymer coating that extends the duration of drug delivery to match the longer healing duration often experienced in more complex cases. METHODS: The RESOLUTE trial was a prospective, nonrandomized, multicenter study of the Resolute stent in 139 patients with de novo coronary lesions with reference v..

View full abstract